What Dr Ashleys does

Dr Ashleys (operating as Zoar Limited) is a Cayman Islands-incorporated pharmaceutical company founded in 2012 that manufactures specialized active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, and anti-cancer medications. The company employs 101-250 people and produces over 300 million annual medical doses delivered to disease epicenters worldwide. Its proprietary low-cost manufacturing technology enables it to produce the industry's lowest-cost malaria drug and to rank as the world's third-largest contract manufacturer of quinine salts and the market leader in antimalarial APIs. The company holds 60 issued patents and 60+ pending patents, a portfolio expanded through its announced reverse merger with Impact BioMedical Inc. targeted for NYSE American listing by July 2026.

The company serves government health ministries and healthcare providers in Africa (addressing 94% of global malaria cases) and Southeast Asia, where its anti-cancer drugs are approved in Malaysia with pending distribution throughout the region. Its business model operates across three revenue streams: API manufacturing and direct sales, orphan drug manufacturing for rare diseases, and contract development and manufacturing organization (CDMO) services for pharmaceutical companies globally. The CDMO segment provides third-party manufacturing services helping pharmaceutical companies bring new drugs to market. Distribution occurs through B2B contracts with government health systems and direct sales to enterprise healthcare buyers rather than retail channels.

The company is led by CEO/CFO Daphne Huang (former CFO at Taro Pharmaceuticals, Human well Healthcare USA, and Gorilla Technology Group), COO Markland Anthony (30+ years in Southeast Asia markets, previously VP Operations at Fung Shing Chemicals Limited), and founder/visionary leader Dr. Kanans Visvanants FRSC, a second-generation pharmaceutical and chemical engineer. The company has minimal disclosed revenue, with its only public revenue figure being $32,000 from the newly acquired Celios air purification product line for fiscal year 2025.

Name

Dr Ashleys

Legal name

Zoar Limited

Website

https://drashleys.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Dr Ashleys (Zoar Limited) is a pharmaceutical manufacturer specializing in low-cost APIs, orphan drugs for rare diseases, and anti-cancer medications, serving government health ministries and healthcare providers across Africa and Southeast Asia with over 300 million annual doses.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Orphan drugs
• Anti-malarial drugs
• Contract drug manufacturing

Headquarters

HQ city

Grand Cayman

HQ country

Cayman Islands

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (API): Manufacturing and sale of active pharmaceutical ingredients for various therapeutic areas including oncology, hormonal therapies, antibiotics, cardiovascular, and neurological disorders
2. Orphan Drugs: Specialized manufacturing of orphan drugs for rare diseases, addressing the underserved and limited production market
3. CDMO Services: Contract Development and Manufacturing Organization services helping pharmaceutical companies bring new drugs to market efficiently

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Dr Ashleys (operating as Zoar Limited) develops and manufactures specialized and complex active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, patented anti-malarial drugs, and low-cost anti-cancer drugs using proprietary manufacturing technology. The company also operates a Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical companies bring new drugs to market, delivering over 300 million annual medical doses to disease epicenters globally.

Product overview

Dr Ashleys (operating as Zoar Limited) is a global pharmaceutical manufacturer and Contract Development and Manufacturing Organization (CDMO) offering a portfolio of specialized products including Active Pharmaceutical Ingredients (API), Orphan Drugs, and manufactured treatments. The company's product portfolio includes malaria drugs (industry's lowest cost), anti-cancer drugs (approved in Malaysia), and the recently acquired Celios air purification product line. Operations span across critical health areas including cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases, providing over 300 million annual medical doses to the world's disease epicenters.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 263 million annual malaria cases addressed through low-cost drugs
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Sentinel Brokers CompanyminorChannel Partner/ Reseller/ Distributor · 31 March 2026Sentinel Brokers Company received FINRA approval to serve as an underwriter for corporate securities offerings, supporting the merged entity's public market activities.
• Impact BioMedical Inc.coreStrategic or Co-development Partner · 23 June 2025Dr. Ashleys Limited, a Hong Kong-based pharmaceutical company, announced a strategic merger agreement with Impact BioMedical Inc., a Texas-based biopharmaceutical developer. The merger aims to create a new publicly traded entity on NYSE American, leveraging Impact BioMedical's patent portfolio and expanding global reach and development capabilities. The merger is targeted for completion by July 1, 2026 and is structured as a reverse merger transaction.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Strides Pharma: Indian generic pharma manufacturer with strong presence in Africa, SE Asia, and other emerging markets. Comparable to Dr Ashleys in affordable generic drugs and emerging-market distribution.
• Cambrex: Small-molecule API and finished dosage CDMO. Directly comparable to Dr Ashleys' small-molecule API and drug-product CDMO offering.
• Ipca Laboratories: Indian API and generic manufacturer with a leading global position in antimalarial APIs. One of the closest direct peers to Dr Ashleys in the low-cost antimalarial API segment.
• Aurobindo Pharma: Large Indian generic and API manufacturer with a global footprint and significant antimalarial API share. Directly comparable to Dr Ashleys on low-cost API manufacturing and emerging-market drug distribution.
• Natco Pharma: Indian specialty generic and API manufacturer with oncology focus. Closely comparable to Dr Ashleys in low-cost oncology and specialty generics.
• Cipla: Major Indian generic pharmaceutical manufacturer with a strong antimalarial and respiratory franchise, particularly in Africa. Highly comparable to Dr Ashleys in low-cost generic API manufacturing and emerging-market distribution.
• Lupin Pharmaceuticals: Indian generic and specialty pharma with significant API capabilities. Comparable to Dr Ashleys across generic APIs and emerging-market distribution.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad API and finished-dose capabilities. A broad incumbent peer in the generic and API space where Dr Ashleys competes on cost.
• Mylan / Viatris: Global generic and specialty pharma with significant antimalarial (including quinine) franchise and broad emerging-market distribution. A broad incumbent comparable to Dr Ashleys in antimalarials and global generics.
• Catalent: Global CDMO serving pharma and biotech customers across dosage forms. A broad incumbent CDMO peer reflecting Dr Ashleys' CDMO service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr Ashleys